NextCure Releases Positive Phase 1 Data for SIM0505 in Gynecologic Cancers at ASCO 2026
NextCure, Inc. (Nasdaq: NXTC) and its partner Simcere Zaiming Pharmaceutical Co., Ltd. have announced highly encouraging results from the Phase 1 dose escalation study of their novel antibody-drug conjugate (ADC), SIM0505, targeting Cadherin-6 (CDH6) for patients with gynecologic cancers. These results were presented at the American Society for Clinical Oncology (ASCO) 2026 meeting, a significant milestone likely to attract substantial investor attention.
Key Highlights from the Report
- SIM0505 Shows Promising Efficacy in Challenging Patient Populations:
- In patients with heavily pretreated gynecologic cancers, including platinum-resistant ovarian cancer (PROC) and uterine serous carcinoma (USC), SIM0505 demonstrated a 55% objective response rate (ORR) at 12 weeks within the therapeutic dose range (4.8 – 8.0 mg/kg).
- Breakdown of ORR:
- Ovarian cancer: 52.9% (9/17 patients)
- Uterine serous carcinoma (USC): 66.7% (2/3 patients)
- These response rates are substantially higher than the typical 10–25% ORR seen with current therapies in PROC, where median overall survival is approximately 11 months.
- Responses were observed across a range of CDH6 expression, suggesting broad applicability.
- Favorable and Manageable Safety Profile:
- Adverse events were mainly Grade 1/2 and hematological or gastrointestinal (nausea, vomiting).
- Grade 3/4 toxicities were also primarily hematological and considered manageable without primary prophylaxis.
- Only three patients discontinued due to treatment-related adverse events out of 59 enrolled.
- Global and Diverse Patient Population:
- The study enrolled 59 patients (25 in the U.S., 34 in China), with a median age of 58 years (range 42–78) and a median of five prior systemic therapies (range 1–12), reflecting a truly refractory population.
- Majority were women (96.6%), with a racial breakdown of 57.6% Asian, 33.9% White, 5.1% Black/African American, and 3.4% Other.
- Regulatory and Developmental Progress:
- SIM0505 has received Fast Track Designation from the U.S. FDA for PROC, potentially speeding the path to pivotal trials and market entry.
- A Phase 1 dose optimization segment has been launched globally, with a goal to enroll up to 120 patients across the U.S., Canada, EU, and China, focusing initially on PROC.
Strategic and Price-Sensitive Implications for Investors
- Demonstration of Best-in-Class Potential: The robust response rates in a heavily pretreated population, combined with a manageable side effect profile, set SIM0505 apart as a potential best-in-class therapy for gynecologic cancers, especially where current therapies are failing.
- Unmet Medical Need and Market Opportunity: Ovarian and USC cancers are areas of significant unmet need, with poor outcomes and limited treatment advancements. The promising data could position NextCure as a leader in this therapeutic space.
- Advancement to Pivotal Studies: Positive Phase 1 data and regulatory momentum (Fast Track Designation) pave the way for pivotal trials, which, if successful, could drive significant shareholder value through potential partnerships, licensing, or eventual commercialization.
- Global Partnership: The collaboration with Simcere Zaiming, which retains commercial rights in China, Hong Kong, Macau, and Taiwan, leverages international development scale while preserving significant upside for NextCure in the rest of the world.
- Upcoming Catalysts: NextCure is hosting a virtual Key Opinion Leader (KOL) event on June 2, 2026, at 8:00 AM ET to discuss these data—an event that could further shape market sentiment.
Detailed Study Data and Demographics
| All Patients (n=59) | Details |
|---|---|
| Median Age (years) | 58 (range 42–78) |
| Sex (% Female) | 96.6% |
| Race | Asian: 57.6%, White: 33.9%, Black/African American: 5.1%, Other: 3.4% |
| Tumor Type | Ovarian: 78%, USC/Other Endometrial: 16.9%, RCC: 5.1% |
| ECOG 0/1 | 27.1%/72.9% |
| Prior Systemic Regimens | Median 5 (range 1–12) |
About SIM0505
SIM0505 is a novel ADC targeting CDH6 with a proprietary topoisomerase 1 inhibitor payload (CPT116), designed for broad antitumor activity, rapid clearance, and a potentially improved therapeutic window. It is being developed globally, with NextCure holding exclusive rights outside Greater China.
About Ovarian and Uterine Serous Carcinoma
- Ovarian Cancer: Fifth leading cause of cancer death in women, often diagnosed late due to vague symptoms; 5-year survival is 51.6% overall, but 91.7% if detected early.
- Uterine Serous Carcinoma: A rare, aggressive form of endometrial cancer responsible for 40% of uterine cancer deaths, with over half of patients diagnosed at stage III or IV.
Forward-Looking Statements
NextCure cautions that these results are early and subject to the risks and uncertainties inherent in drug development, including clinical, regulatory, and commercial risks. Investors should review full risk disclosures in company SEC filings and not place undue reliance on forward-looking statements.
Investor Contacts
- Timothy Mayer, PhD, Chief Operating Officer, NextCure, Inc. ([email protected], (240) 762-6486)
- Mike Moyer, Managing Director, LifeSci Advisors, LLC ([email protected], (617) 308-4306)
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors should conduct their own due diligence and consult with professional advisors before making investment decisions. The information is based on company disclosures and may be subject to change or revision. Forward-looking statements are inherently uncertain, and actual results may differ materially.
